| Todd C Campbell, MD | |
|
880 Century Drive, Mechanicsburg, PA 17055 | |
| (717) 691-3235 | |
| (717) 691-3243 |
| Full Name | Todd C Campbell |
|---|---|
| Gender | Male |
| Speciality | General Surgery |
| Experience | 27 Years |
| Location | 880 Century Drive, Mechanicsburg, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1710986682 | NPI | - | NPPES |
| 1015292910001 | Medicaid | PA | |
| 1250401 | Other | PA | AETNA HMO |
| 30033052 | Other | PA | KEYSTONE MERCY |
| 37167 | Other | PA | HEALTH PARTNERS |
| 201093283 | Other | NC | GROUP TAX ID # |
| 101529291001 | Medicaid | PA | |
| 10152929101 | Other | PA | AMERICHOICE |
| 7211833 | Other | PA | AETNA |
| 891347V | Medicaid | NC | |
| 2702925000 | Other | PA | BCBS |
| 83031939 | Other | PA | CIGNA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208600000X | Surgery | 200300950 (North Carolina) | Secondary |
| 208600000X | Surgery | MD428316 (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Jefferson Stratford Hospital | Stratford, NJ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Integrated Wound Specialists Of Elizabeth Llc | 6002097953 | 4 |
News Archive
Today's Caregiver, the first national magazine for all family and professional caregivers, and caregiver.com awarded its 2009 Caregiver Friendly® Award to MediPACK, the Reeves-Sain product which provides organized daily dosage packages for its customers.
A new survey from the Alcohol and Drug Foundation has found that 12 percent of Australians have begun consuming alcohol on a daily basis since the coronavirus pandemic began a few months back. The survey showed that many Australians who did not drink regularly before have picked up the habit.
Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that additional claims for the patent family "Internalizing anti-CD74 antibodies and methods of use," were issued as U.S. Patent No. 7,772,373. The new patent, which will expire in March 2023, covers any humanized antibodies that compete for binding to CD74 with milatuzumab, or bind to the same epitope as milatuzumab.
Technology that can detect the length of small DNA structures in cancer cells could hold the key to predicting the outcome of patients with two different types of blood cancer.
Genta Incorporated announced today the presentation of results from two dose-ranging trials of tesetaxel, the Company's novel oral tubulin inhibitor. Results showed potential activity in patients with taxane-resistant cancers, along with no evidence of hypersensitivity and a low incidence of nerve damage, both of which are common side effects of standard taxanes.
› Verified 3 days ago
| Entity Name | Integrated Wound Specialists Of Elizabeth Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437478898 PECOS PAC ID: 6002097953 Enrollment ID: O20110224000671 |
News Archive
Today's Caregiver, the first national magazine for all family and professional caregivers, and caregiver.com awarded its 2009 Caregiver Friendly® Award to MediPACK, the Reeves-Sain product which provides organized daily dosage packages for its customers.
A new survey from the Alcohol and Drug Foundation has found that 12 percent of Australians have begun consuming alcohol on a daily basis since the coronavirus pandemic began a few months back. The survey showed that many Australians who did not drink regularly before have picked up the habit.
Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that additional claims for the patent family "Internalizing anti-CD74 antibodies and methods of use," were issued as U.S. Patent No. 7,772,373. The new patent, which will expire in March 2023, covers any humanized antibodies that compete for binding to CD74 with milatuzumab, or bind to the same epitope as milatuzumab.
Technology that can detect the length of small DNA structures in cancer cells could hold the key to predicting the outcome of patients with two different types of blood cancer.
Genta Incorporated announced today the presentation of results from two dose-ranging trials of tesetaxel, the Company's novel oral tubulin inhibitor. Results showed potential activity in patients with taxane-resistant cancers, along with no evidence of hypersensitivity and a low incidence of nerve damage, both of which are common side effects of standard taxanes.
› Verified 3 days ago
| Entity Name | Pro Health One Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053714584 PECOS PAC ID: 2466778089 Enrollment ID: O20190326002649 |
News Archive
Today's Caregiver, the first national magazine for all family and professional caregivers, and caregiver.com awarded its 2009 Caregiver Friendly® Award to MediPACK, the Reeves-Sain product which provides organized daily dosage packages for its customers.
A new survey from the Alcohol and Drug Foundation has found that 12 percent of Australians have begun consuming alcohol on a daily basis since the coronavirus pandemic began a few months back. The survey showed that many Australians who did not drink regularly before have picked up the habit.
Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that additional claims for the patent family "Internalizing anti-CD74 antibodies and methods of use," were issued as U.S. Patent No. 7,772,373. The new patent, which will expire in March 2023, covers any humanized antibodies that compete for binding to CD74 with milatuzumab, or bind to the same epitope as milatuzumab.
Technology that can detect the length of small DNA structures in cancer cells could hold the key to predicting the outcome of patients with two different types of blood cancer.
Genta Incorporated announced today the presentation of results from two dose-ranging trials of tesetaxel, the Company's novel oral tubulin inhibitor. Results showed potential activity in patients with taxane-resistant cancers, along with no evidence of hypersensitivity and a low incidence of nerve damage, both of which are common side effects of standard taxanes.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Todd C Campbell, MD 880 Century Drive, Mechanicsburg, PA 17055 Ph: (717) 691-3235 | Todd C Campbell, MD 880 Century Drive, Mechanicsburg, PA 17055 Ph: (717) 691-3235 |
News Archive
Today's Caregiver, the first national magazine for all family and professional caregivers, and caregiver.com awarded its 2009 Caregiver Friendly® Award to MediPACK, the Reeves-Sain product which provides organized daily dosage packages for its customers.
A new survey from the Alcohol and Drug Foundation has found that 12 percent of Australians have begun consuming alcohol on a daily basis since the coronavirus pandemic began a few months back. The survey showed that many Australians who did not drink regularly before have picked up the habit.
Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that additional claims for the patent family "Internalizing anti-CD74 antibodies and methods of use," were issued as U.S. Patent No. 7,772,373. The new patent, which will expire in March 2023, covers any humanized antibodies that compete for binding to CD74 with milatuzumab, or bind to the same epitope as milatuzumab.
Technology that can detect the length of small DNA structures in cancer cells could hold the key to predicting the outcome of patients with two different types of blood cancer.
Genta Incorporated announced today the presentation of results from two dose-ranging trials of tesetaxel, the Company's novel oral tubulin inhibitor. Results showed potential activity in patients with taxane-resistant cancers, along with no evidence of hypersensitivity and a low incidence of nerve damage, both of which are common side effects of standard taxanes.
› Verified 3 days ago
Mr. Leo D Farrell, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 2025 Technology Pkwy, Ste 204, Mechanicsburg, PA 17050 Phone: 717-732-9000 Fax: 717-732-9011 | |
Andrew V Kriegel, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 950 Woodland St, Mechanicsburg, PA 17055 Phone: 717-988-8020 Fax: 717-221-5567 | |
Angela M Sotohamlin, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 880 Century Dr, Mechanicsburg, PA 17055 Phone: 717-691-3235 Fax: 717-691-3243 | |
Dr. Frederick Lorenzo, MD Surgery Medicare: Not Enrolled in Medicare Practice Location: 2025 Technology Pkwy, Ste G 07, Mechanicsburg, PA 17050 Phone: 717-791-2440 Fax: 717-791-2441 | |
John A Rossi, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 2025 Technology Pkwy, Suite 304, Mechanicsburg, PA 17050 Phone: 717-791-2800 Fax: 717-791-2828 | |
Mai Dang Gandhi, DO Surgery Medicare: Medicare Enrolled Practice Location: 2025 Technology Pkwy Ste 212, Mechanicsburg, PA 17050 Phone: 717-988-1450 Fax: 717-221-5544 | |
Dr. Nathalie Lavallee, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 950 Woodland St, Mechanicsburg, PA 17055 Phone: 717-988-8020 |